Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm
- 980 Downloads
Bazedoxifene and raloxifene were evaluated in the treatment of postmenopausal osteoporosis from health economic perspective in Europe. Based on a computer-based algorithm calculating efficacy of the treatments, bazedoxifene appears to be a cost-effective strategy compared to raloxifene, particularly in patients at high fracture risk.
The purpose of this study was to compare cost-effectiveness of bazedoxifene and raloxifene in eight European countries: Belgium, France, Germany, Ireland, Italy, Spain, Sweden, and the UK.
The Fracture Risk Assessment Tool, which is a computer-based algorithm to calculate fracture probability using clinical risk factors alone or with bone mineral density, was incorporated in a Markov Tunnel model to evaluate cost-effectiveness of bazedoxifene 20 or 40 mg vs. raloxifene 60 mg in postmenopausal osteoporotic women. The efficacy of bazedoxifene and raloxifene for vertebral and non-vertebral fractures was measured as a function of the 10-year probability of a major osteoporotic fracture. The model estimated the incremental cost-effectiveness ratio and net monetary benefit (NMB) from a healthcare perspective, given the willingness to pay €30,000.
In postmenopausal osteoporotic women, bazedoxifene was a cost saving strategy compared to raloxifene in the countries studied. The median NMB of bazedoxifene compared to raloxifene increased monotonically with the 10-year fracture probability. In general, the median NMB became greater than 0 in women with 10-year probabilities of a major osteoporotic fracture between 5 and 10 % or above. The impact on results by varying the assumptions in the model was examined in sensitivity analysis.
Bazedoxifene appears to be a cost-effective strategy compared to raloxifene for the treatment of postmenopausal osteoporotic women in Europe, particularly in patients at high fracture risk.
KeywordsBazedoxifene Cost-effectiveness Fracture FRAX Osteoporosis Raloxifene
This study was sponsored by Pfizer. Kun Kim and Axel Svedbom are employees of OptumInsight, who were paid consultants to Pfizer in connection with the development of this manuscript. The economic modeling and validation work was performed at OptumInsight, and OptumInsight is also responsible for the data storage.
Conflicts of interest
Xuemei Luo is an employee of Pfizer, and Santosh Sutradhar was an employee of Pfizer at the time this work was conducted. As employees of OptumInsight, Kun Kim and Axel Svedbom have provided consultancy services to numerous companies involved in the marketing of treatment for osteoporosis.
- 2.Hernlund E, Svedbom A, Ivergard M, Compston J, Joonsson B, Kanis J (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Archives of Osteoporosis (in press)Google Scholar
- 3.Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 18:1947–1954. doi: 10.1359/jbmr.2003.18.11.1947 PubMedCrossRefGoogle Scholar
- 9.Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 282:637–645PubMedCrossRefGoogle Scholar
- 10.Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial *. J Bone Miner Res 23:1923–1934PubMedCrossRefGoogle Scholar
- 12.Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD (2011) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351–363. doi: 10.1007/s00198-011-1691-1 PubMedCrossRefGoogle Scholar
- 13.Tremollieres FA, Pouilles JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P (2010) Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 25:1002–1009. doi: 10.1002/jbmr.12 PubMedCentralPubMedCrossRefGoogle Scholar
- 14.Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj FG, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411PubMedCrossRefGoogle Scholar
- 15.Committee for Medicinal Products for Human Use (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. CHMP, LondonGoogle Scholar
- 17.Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 22:2347–2355. doi: 10.1007/s00198-010-1474-0 PubMedCrossRefGoogle Scholar
- 18.McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817PubMedCrossRefGoogle Scholar
- 19.McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480–1486. doi: 10.1002/jbmr.1606 PubMedCrossRefGoogle Scholar
- 23.The Belgian Health Care Knowledge Centre (2008) Guidelines for pharmacoeconomic evaluations in Belgium: KCE reports 78C. The Belgian Health Care Knowledge Centre (KCE), BrusselsGoogle Scholar
- 24.NICE (2008) Guide to the methods of technology appraisal. http://www.nice.org/uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed June 2008
- 26.Health Information and Quality Authority (2010) Guidelines for the economic evaluation of health technologies in Ireland. Health Information and Quality Authority, CorkGoogle Scholar
- 27.Capri S, Ceci A, Terranova L, Merlo F, Mantovani L (2001) Guidelines for economics evaluations in Italy: recommendations from the Italian group of pharmacoeconomic stuides. Drug Inf J 35:189–201Google Scholar
- 28.Sorenson C, Drummond M, Kanavos P (2008) Ensuring value for money in health care: the role of health technology assessment in the European Union. European Observatory on Health Systems and Policies. Observatory Studies Series No.11Google Scholar
- 30.Cox DR, Oakes D (1984) Analysis of survival data. Monographs on statistics and applied probability 21. Chapman & Hall, LondonGoogle Scholar
- 32.Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRefGoogle Scholar
- 34.EMEA (2009). Committe for medicinal products for human use—summary of positive opinion for Conbriza. EMEA, London, 19 February 2009Google Scholar
- 35.Federaal Ministerie van Sociale Zaken, Volksgezondheid en Leefmilieu. Bestuur van de gezondheidszorgen. Commissie voor toezicht op en evaluatie van statistische gegevens die verband houden met de medische activiteiten in de ziekenhuizen. Rijksadministratif centrum. Brussel. Upon written requestGoogle Scholar
- 38.Kanis J (2008) Assessment of osteoporosis at the primary health-care level. Technical report. WHO Collaborating Centre, University of Sheffield, , UKGoogle Scholar
- 39.IARC (2008). GLOBOCAN 2008. Cancer incidence, mortality and prevalence worldwide in 2008. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr/
- 40.Wilmoth JR, Shkolnikov V (2012). The human mortality database (HMD). Online source http://www.mortality.org/
- 43.Poor G, Atkinson EJ, O'Fallon WM, Melton LJ III (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop 319:260–265.Google Scholar
- 49.NICE (2008) Osteoporosis—secondary prevention including strontium ranelate: appraisal consultation document. www.nice.org.uk
- 54.Kanis J (2001). Epidemiology and costs of fractures in the UK—background document for male osteoporosis model. Personal communication 2001Google Scholar
- 57.The World Bank (2010). Global purchasing power parities and real expenditures. The World Bank Database 2010. http://data.worldbank.org/. Accessed Dec 2011
- 58.Statistics Belgium (2012) www.statbel.fgov.be. Accessed Oct 2012
- 59.Stevenson M, Davis S (2006). Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. NICE, LondonGoogle Scholar
- 61.Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:185–192. doi:S0378512296010997Google Scholar
- 62.Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637–650. doi: 10.1007/s00198-010-1291-5 PubMedCrossRefGoogle Scholar
- 63.Zethraeus N, Strom O, Borgstrom F (2006) What is the risk of institutionalization after hip fracture? Osteoporos Int 17(Suppl 1):57–58Google Scholar
- 65.The National Board of Health and Welfare in Sweden (2010). http://www.socialstyrelsen.se. Accessed Dec 2010
- 69.Stadsledningskontoret. Stockholms stads budgetavräkning. 2003Google Scholar
- 72.Foundation NO (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoorosis Int 8:1–88Google Scholar
- 75.Ström O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269–280. doi: 10.1080/17453670710015094 PubMedCrossRefGoogle Scholar
- 76.Kanis JA, Oden A, Johnell O, Johansson H, de Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ III, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRefGoogle Scholar
- 79.Ström O, Borgstrom F, Kleman M, McCloskey E, Odén A, Johansson H, Kanis J (2010). FRAX® and its applications in health economics. Cost-effectiveness and intervention thresholds. BONE 47:430–437Google Scholar
- 80.Hiligsmann M, Sedrine WB, Reginster JY (2012). Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. J Bone Miner Res. doi: 10.1002/jbmr.1819
- 81.Darba J, Perez N, Kaskens L, Racketa J, Rejas J (2011). A cost-effectiveness model of bazedoxifene versus raloxifene for the prevention of fractures in Spanish postmenopausal women. European Congress on Osteoporosis and Osteoarthritis (ECCEO11-IOF) 2011, Valencia (Spain)Google Scholar
- 84.National Services Scotland (2009). The patient journey post hip fracture: what constitutes rehabilitation?—A report from the Scottish hip fracture audit. Scottish Hip Fracture Audit 2009. http://www.shfa.scot.nhs.uk/